Aida Announces Definitive Agreement and Provides Corporate

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
576
Aida Announces Definitive Agreement and Provides Corporate Update on Transaction with 10375977 Canada Inc.

VANCOUVER, British Columbia, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Aida Minerals Corp. ("AMC" or the "Company") (CSE:AMC) (FRANKFURT: 2AD ) wishes to provide an update on the previously announced letter of intent (the "LOI") ( October 6, 2017 ) to acquire 100% of 10375977 Canada Inc., a blockchain technology company doing business as Greenstream ( "Greenstream" ). The Company has completed the due diligence process, the definitive agreement has been signed by both parties and the transaction will submitted to the Canadian Securities Exchange (the "CSE" ) for review.

The definitive agreement has resulted in a fundamental change for AMC pursuant to Canadian Securities Exchange Policy 8. Accordingly, AMC will seek approval to the transaction from shareholders, and will completing a Form 2A listing statement and file the documents set out in CSE Policy 2 concurrently with filing the information circular in respect of an annual general and special meeting of shareholders to approve the transaction. This meeting is scheduled for December 28, 2017. The target closing date remains subject to the receipt of the required regulatory and shareholder approvals. Once those approvals have been accomplished, the Company will request permission to resume trading.

Once the transaction is completed, AMC will change the company name to BLOK Technologies Inc. (“BLOK”) to better reflect the change to a technology issuer. The Company will continue to trade on the CSE but will change its symbol to BLK, and the Board of Directors and management team of the Company will be reconstituted.

About Blockchain Blockchain is an open, distributed ledger technology protocol that ensures trust, accuracy and auditability of transactions. Many believe that blockchain will transform the way business is done.  Blockchain systems can record transactions between two parties efficiently and in a verifiable and permanent way. Once recorded, the data in any given block is immutable, meaning it cannot be altered retroactively without the alteration of all subsequent blocks by the majority of the network.

Blockchain systems are secure, decentralized and eliminate the need for central third parties to verify trust within the transaction. This makes blockchain ideally suited for recording of commercial transactions, inventory management, events, personal identity records, and the traceability of goods amongst producers and the supply chain.

Blockchain has significant benefits in the legalized cannabis industry for both companies and regulators enabling secure supply chain management and regulatory compliance like never before. This enables complete tax compliance at the municipal, provincial, and federal levels.

About Greenstream Greenstream is engaged in the development of a blockchain-enabled supply chain management platform for the legalized cannabis industry. The federal government has laid out a roadmap to have cannabis legalized nationwide by July 2018. With this in mind, Greenstream is in the process of developing a technology architecture to address the supply management needs for this new regulatory environment, providing the industry the ability to manage from 'seed to sale'. The Greenstream architecture calls for three layers of development including: smart contract processing, POS and ID database integrations and integration with existing inventory management and enterprise management platforms. When fully deployed, there will be multiple stakeholders for the Greenstream platform, including: licensed producers, distributors, government regulators, dispensaries, and software providers.

The Company would also like to announce that it has granted stock options exercisable for the issuance of up to 150,000 common shares of the Company (the "Stock Options" ) at a price of $1.00 for a period of twelve months to directors, employees and consultants.

For further information, please contact:

James Hyland, B.Comm. VP Corporate Development (604) 442-2425 jamie@aidaminerals.co

ON BEHALF OF THE BOARD OF DIRECTORS

“Donald Gordon” Director

Statements in this news release may be viewed as forward-looking statements. Such statements involve risks and uncertainties that could cause actual results to differ materially from those projected. There are no assurances the company can fulfill such forward-looking statements and the company undertakes no obligation to update such statements. Such forward-looking statements are only predictions; actual events or results may differ materially as a result of risks facing the company, some of which are beyond the company’s control. 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 38

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 47

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 44

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 38

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 43

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 35

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into AppLovin Corporation's Alleged Fraud

Updated Category News Views 386

Investigation into AppLovin Corporation In recent news, a substantial class action lawsuit has emerged against AppLovin Corporation (NASDAQ: APP). This national law firm, known for advocating for investors, aims to hold the company accountable for alleged securities law violations. Understanding the Class Action Lawsuit This lawsuit pertains to any individuals or entities...

Continue Reading
Safe Harbor Financial Expands Support for Cannabis Operators

Updated Category News Views 33

Safe Harbor Financial Takes Bold Step in Cannabis Financing In a remarkable move, Safe Harbor Financial has successfully arranged a secured credit facility valued at $1.07 million. This milestone supports a cannabis operator, marking a significant step in bolstering financial services within the cannabis industry. With their expertise in facilitating innovative financial...

Continue Reading
Nidec Corporation Faces Securities Investigation: Key Insights

Updated Category News Views 224

Understanding Nidec Corporation's Current Challenges Nidec Corporation is undergoing scrutiny due to serious allegations in its business practices. This Japanese manufacturer, known for its electronic components, faces potential claims of issuing misleading information to its investors. Recent developments have raised questions about its transparency and accountability in...

Continue Reading
Understanding HCI Group's Short Interest Trends and Insights

Updated Category News Views 126

An Overview of HCI Group's Short Interest HCI Group's short interest has sparked interest among traders and investors alike, showing a recent increase of 7.38% from the previous report. This shift indicates that there are currently around 404 thousand shares sold short, comprising 4.95% of the company’s total tradable shares. Observing the trading volume, it has been...

Continue Reading
Fresenius Kabi Introduces New Epinephrine Injection for Patients

Updated Category News Views 151

Fresenius Kabi Launches Epinephrine Injection, USP Fresenius Kabi, a proud branch of the Fresenius organization, has taken a significant step in enhancing its pharmaceutical portfolio in the United States by making available Epinephrine Injection, USP. This launch positions Fresenius Kabi at the forefront as it becomes the first company to offer a generic 1mg/1mL vial of...

Continue Reading